By Angela Chen 
 

Amgen Inc. said Thursday that a trial of its Vectibix showed positive survival results in patients with a certain type of colorectal cancer.

The phase 3 trial compared the survival benefit of Vectibix, or panitumumab, in a group of patients with chemorefractory wild-type KRAS colorectal cancer. Patients were randomized to receive either Vectibix and best supportive care every two weeks, or best supportive care alone. More patients taking the treatment survived compared to those who had not.

Colorectal cancer is the third most commonly diagnosed cancer and the third leading cause of cancer death in both men and women in the U.S., according to the American Cancer Society.

The Food and Drug Administration approved Vectibix in 2006 as a treatment for a different type of colorectal cancer than the one in the most recent study.

Shares of Amgen, up about 0.2% after the close, are roughly flat this year.

Write to Angela Chen at angela.chen@wsj.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Amgen Charts.
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Amgen Charts.